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may appear within muscle fibres, reinforcing the myopathic 
process in a vicious circle.
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Introduction
Sporadic inclusion body myositis (sIBM) is the most fre-
quent acquired progressive myopathy presenting over 
50 years of age in Western populations [13], albeit rare. For 
example, a recently published Dutch study from a tertiary 
referral centre identified only 64 patients from 7 specialized 
neuromuscular centres in a country with 16 million inhab-
itants [26], giving an estimated prevalence of 4.9 patients 
per million inhabitants in The Netherlands [13]. This may 
be an underestimate since sIBM can mimic other forms of 
myositis including polymyositis, hereditary myopathies of 
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matologists recognize this disorder which may, through 
clinical and pathological similarities, mimic other myo-
pathies, especially polymyositis. Whereas polymyosi-
tis responds to immunosuppressant drug therapy, sIBM 
responds poorly, if at all. Controversy reigns as to whether 
sIBM is primarily an inflammatory or a degenerative myo-
pathy, the distinction being vitally important in terms 
of directing research for effective specific therapies. We 
review here the pros and the cons for the respective hypoth-
eses. A possible scenario, which our experience leads us 
to favour, is that sIBM may start with inflammation within 
muscle. The rush of leukocytes attracted by chemokines 
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pression. If the protein degradation systems are overloaded 
(possibly due to genetic predisposition, particular HLA-I 
subtypes or ageing), amyloid and other protein deposits 
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the limb girdle phenotype (see below) and the lower motor 
neuron variant of ALS. sIBM is a disabling (but not in itself 
lethal) muscle disease with first symptoms typically pre-
senting in the 6th decade of life [17]. The natural history of 
the condition is one of the relentless progression of weak-
ness, with an estimated loss of strength between 3.5 and 
5.5 % per year [17, 26]. Pneumonia, secondary to immobil-
ity, respiratory muscle weakness and aspiration due to dys-
phagia, is a common terminal event [17, 26].
There is a highly characteristic pattern of limb mus-
cle involvement with selective weakness of finger flexion 
(Fig. 1a, b) and knee extension (Fig. 1c). This pattern was 
noted by early investigators but considered of second-
ary importance to pathological features in establishing the 
diagnosis [42]. More recently, it has been proposed that 
clinical features are paramount and may allow the diag-
nosis of sIBM in the absence of what had previously been 
considered to be canonical pathological features (Table 1) 
[19, 82]. Such criteria were assessed prospectively in a 
large cohort of IBM (n = 200) and non-IBM patients 
with other neuromuscular disorders (n = 171) [59]. They 
are highly specific (range 98–100 %) with a sensitivity of 
77–84 % for probable IBM depending on the criteria used 
[19, 82]. Furthermore in this study, the authors observed 
that the combination of finger flexor or quadriceps weak-
ness and endomysial inflammation, and either invasion of 
non-necrotic muscle fibres or rimmed vacuoles permitted 
the diagnosis of sIBM with 90 % sensitivity and 96 % spec-
ificity [59]. 
Until recently, the diagnostic gold standard was consid-
ered to be certain pathological criteria. These criteria [42] 
include the presence of inflammatory infiltrates with mono-
nuclear cell invasion of non-necrotic muscle fibres (partial 
invasion, Fig. 2a), vacuolated muscle fibres (Fig. 2b), and 
intracellular amyloid protein deposits [detected by fluores-
cent methods (Congo red, or p-FTAA dye (fluorescent thio-
phene) [52], Fig. 2c] or 15–18 nm tubulofilaments in the 
cytoplasm or the nucleus by electron microscopy (Fig. 2d). 
Electron microscopy is rarely used in everyday practice 
and the original diagnostic criteria, without formal agree-
ment, have been supplemented with the detection of vari-
ous proteins by immunohistochemistry [e.g. with antibod-
ies against phosphorylated tau, TDP43, or p62 (Fig. 2 e, f) 
[22, 32] see below].
Furthermore, it has been noted frequently that the above-
mentioned canonical pathological features may be missing 
in patients with typical clinical features of the condition 
(leading to a sensitivity of only 11 % [59]), particularly at 
first presentation, perhaps in part due to a small biopsy not 
reflecting the whole pathological picture [21, 24, 32, 77]. 
Repeat biopsy later in the course of the disease may show 
canonical features absent at presentation, either because 
they evolve with time (see below), or reflecting sampling 
error.
Finally, Pestronk [75] proposed classifying sIBM path-
ologically as an inflammatory myopathy with vacuoles, 
aggregates and mitochondrial pathology (IM-VAMP); but 
regarding the clinical features of sIBM, he did not estimate 
the specificity nor the sensitivity of such pathological cri-
teria (which indeed has been the case with other proposed 
criteria). Accordingly, mitochondrial abnormalities (COX 
negative and/or ragged red fibres) and partial invasion have 
Fig. 1  Clinical features of sIBM. a Finger flexors weakness (arrow maximum obtained by this patient: 5.6 kg, normal >21 kg for a woman at 
70 years old), and b atrophy (arrows). c Quadriceps atrophy (arrows) for a man at 75 years old
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been shown to provide strong evidence for the diagnosis of 
sIBM [21, 24]. It has been also shown that the increased 
frequency of ragged red fibres, above the level predicted for 
normal ageing, is unique to sIBM and not observed in other 
inflammatory myopathies including polymyositis and der-
matomyositis [79].
These diagnostic difficulties relate to the fact that the 
physiology of sIBM is not yet fully understood and that its 
proposed mechanisms are still debated [39]. In short, the 
canonical pathological features facilitated the initial clini-
cal recognition of sIBM as a specific disorder. Additional 
pathological features have since been recognized (accumu-
lation of various proteins), but no individual pathological 
feature is diagnostic. The stereotypical clinical features can 
allow diagnosis even in the absence of the typical histo-
pathologic picture [21].
Pathogenesis
Amyloid component of sIBM
Included in the canonical pathological criteria, one of the 
main features of this disease is the abnormal accumula-
tion of ubiquitinated proteinaceous congophilic inclu-
sions within some muscle fibres. This was first described 
in 1991 by Mendell et al. [62] who studied the composi-
tion of cytoplasmic and intranuclear filamentous inclusions 
observed by electron microscopy (Fig. 2d) on sIBM mus-
cle biopsies and who observed amyloidogenic birefrin-
gent green deposits after Congo red staining. They also 
observed that the number of amyloid-positive fibres corre-
lated with the number of vacuolated fibres. Perhaps pres-
ciently, the authors noted that “the association of amyloid 
deposits with autophagic vacuoles (i.e. rimmed vacuoles) 
in IBM raises the likely possibility that the filaments rep-
resent a modification of a normal protein within an acidic 
degradative vacuolar compartment” [62]. Shortly after, 
Askanas et al. [9, 10] showed by immunohistochemistry 
that inclusions within vacuolated fibres were immunoreac-
tive with anti-β-amyloid antibodies, and by immunogold 
electron microscopy that β-amyloid protein immunoreac-
tivity was localized in proximity to cytoplasmic tubulo-
filaments [9, 10]. The amyloid-β precursor protein (AβPP) 
overproduction is not yet clarified (for review [12]). AβPP 
is then cleaved to Aβ40 or Aβ42, and oligomers of these 
proteins may form subsequently [8]. We will use the term 
‘β-amyloid’ throughout the review. These β-amyloid pro-
tein deposits are also shown to be accompanied by an 
increase in plasma Aβ42 protein in sIBM blood samples 
as compared to polymyositis patients and control sub-
jects [1]. Nevertheless, this increase is also noticed in the 
blood of dermatomyositis (DM) patients limiting the value 
of this potential biomarker. Again by immunostaining, 
Askanas et al. [11] demonstrated the presence of numer-
ous further molecules known to be associated with specific 
Table 1  The ENMC IBM Research Diagnostic Criteria 2011 [83]
a
 Demonstration of amyloid or other protein accumulation by established methods (e.g. for amyloid Congo red, crystal violet, thioflavin T/S, for 
other proteins p62, SMI-31, TDP-43). Current evidence favours p62 in terms of sensitivity and specificity but the literature is limited and further 
work required
Clinical and laboratory features Classification Pathological features
Duration >12 months Clinico-pathologically  
defined IBM
All of the following:
Age at onset >45 years  Endomysial inflammatory infiltrate
 Rimmed vacuoles
Knee extension weakness ≥hip flexion weakness and/or  
finger flexion weakness >should abduction weakness
 Protein accumulationa or 15–18 nm 
filaments
CK no greater than 15 × ULN
Duration >12 months Clinically defined IBM One or more, but not all, of:
Age at onset >45 years  Endomysial inflammatory infiltrate
Knee extension weakness ≥hip flexion weakness and  
finger flexion weakness >should abduction weakness
 Up-regulation of MHC-I
 Rimmed vacuoles
 Protein accumulationa or 15–18 nm 
filaments
CK no greater than 15 × ULN
Duration >12 months Probable IBM One or more, but not all, of:
Age at onset >45 years  Endomysial inflammatory infiltrate
Knee extension weakness ≥hip flexion weakness or finger  
flexion weakness >should abduction weakness
 Up-regulation of MHC-I
 Rimmed vacuoles
 Protein accumulationa or 15–18 nm 
filaments
CK no greater than 15 × ULN
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degenerative processes, particularly of the central nervous 
system such as phosphorylated tau, ubiquitin, α-synuclein 
and prion protein (for review see [8]). These abnormal pro-
tein aggregates are observed within muscle fibres in the 
form of plaque-like or dotty inclusions [8]. However, pro-
tein deposition may not have the same functional implica-
tions as in the central nervous system. β-amyloid deposits, 
for example, are mostly found extracellularly in Alzhei-
mer’s disease while they are intracellular in muscle fibres 
of sIBM patients.
Before considering further what might be called the 
‘amyloid hypothesis’, it must be noted that not all inves-
tigators have concluded that the accumulation of proteins 
associated with neurodegeneration is of specific signifi-
cance. For example, using a proteomic approach, Parker 
et al. [73] did not find accumulation of such proteins in 
sIBM nor did they detect even one peptide from β-amyloid. 
This lack of detection could be related to limited sensitivity 
of current proteomic technology [95].
Nevertheless, defenders of the theory of β-amyloid-
mediated sIBM myofiber injury have tried to understand 
the physiology of the amyloid deposits by studying protein 
degradation pathways (Fig. 3). One of the two pathways 
for protein degradation is the 26S-proteasome; notably, it 
is responsible for the degradation of abnormal or damaged 
proteins. The 26S proteasome can be divided into two sub-
complexes, the core particle (20S) and the regulatory parti-
cle (19S). The 19S assists in deubiquitination, and unfolds 
ubiquitinated protein substrates that are subsequently trans-
located into an enclosed cavity formed by the 20S unit. Here, 
a variety of catalytic sites degrade the substrate into short 
peptides that are subsequently broken down to amino acids 
by peptidases and recycled by the cell. In sIBM muscle biop-
sies, 26S proteasome subunits (19S and 20S) co-localized by 
immunodetection with phosphorylated tau, ubiquitin and/or 
β-amyloid protein deposits [35]. Paradoxically, even though 
both proteasome subunits were upregulated in sIBM muscle, 
the three main proteolytic activities (trypsin-like, chymot-
rypsin-like and peptidyl-glutamyl-peptide hydrolytic) of the 
20S were dramatically reduced [35]. This is consistent with 
the fact that proteasomes can destroy only soluble proteins 
while aggregates are mainly removed by autophagy [37].
The second pathway of protein degradation is autophagy 
(Fig. 3). A portion of the cytoplasm, organelles, proteins 
Fig. 2  Pathological features of 
sIBM: a partial invasion of a 
myofiber by inflammatory cells 
(Gomori trichrome; original 
magnification ×600). b Intra-
cytoplasmic rimmed vacuoles 
(H&E; original magnification 
×400). c Evidence of intracyto-
plasmic and intravacuolar amy-
loid by staining with pFTAA 
(original magnification ×400). 
d Intracytoplasmic paired heli-
cal filaments illustrated by ultra-
structural examination (scale 
bar represents 0.5 μm). e, f 
Immunohistochemical evidence 
of P62+ aggregates in muscle 
fibres (e original magnification 
×400, f original magnification 
×200)
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and protein aggregates are engulfed by a double-layered 
membrane to form a vesicle that is called an autophago-
some. Next, autophagosomes dock and fuse with lysosomes 
to form autolysosomes where the cargo is degraded by 
acidic hydrolases. The degradation products are transported 
to the cytosol where they are utilized to build new orga-
nelles/proteins or for energy production [88]. Autophagy 
can be selective and can remove specifically damaged orga-
nelles and/or protein aggregates. Different mechanisms 
are involved in the selective recognition of the cargo and 
some are depicted in Fig. 3. Failure of autophagy leads to 
accumulation of cargo and autophagy substrates such as 
p62/SQSTM1, NBR1 and tau. Autophagosomes contain-
ing amyloid precursor protein and β-amyloid proteins can 
be observed at increased frequency in muscle fibres of 
sIBM muscle biopsies, but not in non-myopathic muscle 
or in non-vacuolated myopathic controls [60]. Moreover, 
Nogalska et al. [67] observed markers of autophagy induc-
tion such as LC3-II in sIBM muscle, but at the same time, a 
significant decrease of lysosomal enzyme activities of cath-
epsins D and B, leading to the conclusion that autophagy 
is also impaired during sIBM. The mechanism explain-
ing why autophagy is impaired, and at which level the 
autophagy flux is blocked in sIBM, is still not fully under-
stood (see Fig. 3). It is important now to determine whether 
such failure is secondary to inflammation or is a direct con-
sequence of excessive protein misfolding and aggregation.
Concomitantly p62, a shuttle protein transporting 
poly-ubiquitinated proteins for both the proteasomal and 
lysosomal degradation pathways accumulates within 
muscle fibres into aggregates that are positive for phospho-
rylated tau [68]. This feature is consistent with the failure 
of autophagy. Indeed, one of the most important markers of 
autophagy block is the presence of p62-positive inclusions 
[89] (Fig. 3). Accumulation of another protein, TDP43 [32, 
87], which is one component of the ubiquitinated inclu-
sions in the brain of patients with, for example, frontotem-
poral dementia, may also relate to proteasome dysfunction 
Fig. 3  In sIBM, misfolded proteins start to accumulate into aggre-
gates that are positive for P62 and NBR1. The presence of P62-posi-
tive aggregates is a consequence of impaired protein clearance of pro-
teasome and autophagy/lysosome (Ly) systems that further impacts 
on their activities. Overload of the autophagy system with subsequent 
exhaustion, aspecific absorption and sequestration of the protea-
some on the surface of inclusions describe how aggregates negatively 
affect these systems. Autophagy is characterized by membranes that 
are committed to growth, thus becoming double membrane vesi-
cles, named autophagosome, that surround a ‘portion’ of cytoplasm, 
organelles, glycogen and protein aggregates. Autophagy is triggered 
by the activation of a regulatory complex (containing Vps34, Bec-
lin 1, Vps15, Ambra1, Atg14) that induces LC3 recruitment to the 
nascent autophagosome (isolation membrane). Selective removal 
of organelles including mitochondria (mitophagy, a specific form 
of autophagy) requires several signals. For example in mitophagy, 
Bnip3 factors are recruited on damaged mitochondria and by binding 
LC3 allow the recruitment of the vesicle on the surface of the altered 
mitochondria. Proteins that are committed for lysosomal degradation 
are labelled by polyubiquitin chains and delivered to the autophago-
some by the p62/NBR1 scaffold proteins that bind LC3. Finally, upon 
autophagosome fusion with lysosome the cargo is destroyed and con-
stituents are recycled by the cell to rebuild organelles/proteins or for 
energy purposes. Whether inflammation triggers protein misfolding 
aggregation or blocks the autophagy and proteasome system is still an 
open issue and will certainly be subject of future studies. Dotted lines 
represent unknown mechanisms (Ub = ubiquitin)
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[101]. It has been shown that the conditional knock-out of 
the proteasome (but not of autophagy) in mice induced the 
accumulation of TDP43 [48]. The presence of p62 and/or 
TDP43 accumulations, demonstrated by immunostaining, 
is now recognized as one of the most sensitive pathological 
findings in sIBM [22, 32]. However, the best diagnostic sen-
sitivity (93 %) and specificity (100 %) were obtained by the 
combination of characteristic p62 aggregates and increased 
sarcolemmal and internal major histocompatibility complex 
class I expression or endomysial T cell infiltrates [22].
Thus, in sIBM, accumulation of aggregates seems to 
be related to proteasome and autophagy dysfunctions, 
but with what pathophysiological consequences? Various 
mouse models have attempted to provide further insight. 
A double transgenic mouse, overexpressing APP and the 
presenilin-1 gene under the dependence of a muscle spe-
cific promotor, showed increased Aβ42 levels in skeletal 
muscle and exacerbation of inclusion body myositis-like 
pathology and motor deficits [50]. Moreover, the overex-
pression of the proteolytic fragments of mutant (D187N/Y) 
plasma gelsolin (familial Finnish amyloidosis) also leads 
to muscle weakness, the appearance of vacuoles and an 
increase in proteasome and autophagy markers [71]. Spe-
cific overexpression of a transgenic heavy chain of major 
histocompatibility class I (MHC-I) in myofibers leads to a 
severe myopathy in immunocompetent mice with induc-
tion of stress of the endoplasmic reticulum [65, 66]. It was 
further shown that these changes also occur in immuno-
deficient mice, indicating that in mice this myopathy may 
arise without any contribution of the adaptive immune 
system (i.e. presentation of muscle autoantigens to auto-
reactive CD8+ T cells by MHC-I molecules) [36]. Inter-
estingly in this report, muscle of sIBM patients presented 
similar proteomic features of endoplasmic reticulum stress 
in a fashion that was dependent on the level of intracel-
lular accumulation of MHC-I molecules [36]. It is likely 
that, when the protein degradation systems are overloaded 
(e.g. here by the MHC-I overexpression), proteins are mis-
folded and/or ubiquitinated and their accumulation causes 
a vacuolar myopathy [36]. This situation is also observed 
in patients with a form of hereditary inclusion body myo-
pathy (hIBM) due to p97/VCP mutations, which is another 
molecular complex responsible for the regulation of pro-
tein degradation through the proteasome and autophagy 
[49]. Here again, P62 and TDP-43 accumulate in the cyto-
plasm of p97/VCP mutant-expressing cells and transgenic 
mouse muscle [48]. Furthermore in sIBM, the β-amyloid 
β42 deposits co-localized with dysferlin, which is absent 
from the sIBM muscle fibre sarcolemma (contrary to nor-
mal muscle where dysferlin is localized at the sarcolemma) 
[23]. Knowing that this protein is involved in the sarcolem-
mal repair of muscle fibres [16], this interaction may aggra-
vate the myopathy.
Inflammatory component of sIBM
The second pathological hallmark of sIBM is the pres-
ence of inflammatory infiltrates (Fig. 4). These infiltrates 
are rich in lymphocytes (mostly CD8+ T cells, Fig. 4a) 
and macrophages (Fig. 4b), while CD4+ T cells (Fig. 4c) 
and B lymphocytes (Fig. 4d) are less abundant. CD8+ T 
cell- and macrophage-rich infiltrates are regularly observed 
invading non-necrotic fibres (Fig. 2a) [7]. Invading CD8+ 
T cells express co-stimulatory molecules such as inducible 
T cell co-stimulator (ICOS) which may promote lympho-
cyte activation by providing secondary signals to T cells in 
addition to T cell receptor stimulation by antigen, and elicit 
cytotoxic function markers such as perforin [93]. CD8+ T 
cells can be expanded ex vivo from muscle of polymyosi-
tis and sIBM patients. These clones show cytotoxic activ-
ity against autologous myotubes in vitro [46]. We have 
previously demonstrated shared oligoclonal expansions of 
CD8+ cells in both peripheral blood and muscle inflam-
matory infiltrates of sIBM patients (Fig. 4e) [31]. These 
clones persist in repeated muscle biopsies [4], as they do in 
polymyositis [18]. Finally, these expanded cytotoxic CD8+ 
T cells become CD28null [2, 72], a phenotype of chroni-
cally activated and terminally differentiated T cells. To 
develop into functional cytotoxic effectors, CD8+ T cells 
must recognize, via their T cell receptor, specific antigenic 
epitopes presented by the target cells in a MHC-I-restricted 
manner. Not surprisingly then, diffuse overexpression of 
MHC-I is observed on the surface of myofibers in sIBM 
[33] and is even more prominent in sIBM compared to 
other forms of myositis [74], allowing the presentation 
of (today still unknown) antigens to effector T cells. The 
attack of myofibers by cytotoxic T cells seems to be related 
to local inflammation associated with the induction of the 
interferon gamma receptor, up-regulation of several inter-
feron gamma-induced genes [47] and presence of several 
cytokines such as IFN-γ, IL-1β, TNF-α [70] and tumour 
necrosis factor-like weak inducer of apoptosis (TWEAK) 
[64].
On the other hand, immuno-regulatory second signals 
such as programmed death ligand 1 (PD-L1, formerly 
referred to as B7-H1) are also triggered, presumably as a 
negative feedback loop. PD-L1 is expressed in polymy-
ositis, dermatomyositis and sIBM muscle fibres but not 
in normal muscle. Staining is predominantly localized (in 
muscle fibres as well as mononuclear cells) to areas of 
strong inflammation [102]. Furthermore, cultured human 
myoblasts express high levels of PD-L1 after stimula-
tion with the inflammatory cytokine IFN-γ [102]. Another 
mechanism of control of the specific immune responses 
relates to regulatory T cells (Treg). Congenital or acquired 
Treg deficiency causes multi-organ autoimmune disease in 
mice and in humans [20, 55, 98, 103]. We were the first to 
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describe a Treg deficiency (but with normal function) in the 
peripheral blood of sIBM patients [2]. Indeed, we observed 
in 22 sIBM patients, compared to 22 sex- and age-matched 
healthy subjects, that sIBM patients had a decreased fre-
quency of circulating regulatory T cells (CD4+CD25+CD1
27lowFOXP3+, 6.9 ± 1.7 %; vs. 5.2 ± 1.1 %, p = 0.01) that 
displayed normal suppressor function [2].
Also recently, new arguments, coming from microarray 
analyses, have shown that it is not only cellular responses 
that are involved in sIBM but also humoral responses 
[41]. In contrast to normal muscle, immunoglobulin genes 
are the most abundant transcripts in sIBM, and antibody-
secreting plasma cells (CD138+) are frequently observed 
(Fig. 4f) in higher numbers than B cells which remain 
rather rare (Fig. 4d) [41]. Recently, Ray et al. [78] isolated 
single plasma cells by microdissection directly from IBM-
derived muscle tissue sections and analysed a series of 
recombinant immunoglobulins produced from these cells; 
the muscle molecular target of these antibodies appeared 
to be desmin. Of note, anti-desmin antibodies have been 
described in different autoimmune conditions (such as 
lupus and autoimmune thrombocytopenic purpura [94, 97]) 
and might not be of any specific significance, but in inher-
ited desminopathies, clinic-pathological features include 
distal involvement and rimmed vacuoles with amorphous 
deposits [38]. These desmin aggregates co-localized with 
ubiquitinated proteins (and notably mutant ubiquitin which 
is resistant to proteasome degradation) and p62 [69]. It 
is therefore questionable whether those intramuscular 
secreted anti-desmin antibodies participate in proteasome 
dysfunction.
Despite the clear evidence of global immune activa-
tion in sIBM, the question remains as to whether sIBM is 
primarily an inflammatory or a degenerative myopathy. 
If amyloid is the consequence of a primary immune reac-
tion, including secretion of cytokines that increase MHC-I 
expression to such an extent that protein degradation capa-
bilities are overloaded [36], then targeted immune inter-
vention (e.g. biotherapies) at an early stage of the disease 
may be useful. On the contrary, if sIBM is primarily a 
Fig. 4  Composition of the 
inflammatory infiltrate in sIBM 
muscle: a CD8+ cells. b CD68+ 
macrophages. c CD4+ cells. 
d CD20+ B cells. e Clonally 
Vβ1 expanded cells. f CD138+ 
plasma cells
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degenerative disease in which accumulation of unfolded 
proteins causes a secondary immune reaction, immunoin-
tervention may be of limited, if any, benefit. Thus, we will 
review below the pros and the cons for both hypotheses.
Arguments for degeneration as initial event/trigger
The main argument comes from the lack of significant 
beneficial clinical effect from conventional immunosup-
pressant drug therapy. Eight prospective double-blind stud-
ies have shown that conventional immunosuppressants 
(corticosteroids or methotrexate) or immunomodulatory 
regimens (polyvalent immunoglobulins, beta interferon, 
oxandrolone) have minimal or no benefit for sIBM patients 
[14, 28, 30, 43, 44, 57, 84, 100]. It has to be noted that the 
limited number of validated and sensitive disease activ-
ity and damage assessment tools specific for sIBM [45] 
are clearly a limitation in evaluating the clinical trial data, 
and probably all of these studies were underpowered, in 
terms of numbers and duration. Thus, we cannot be abso-
lutely certain of complete lack of response to such treat-
ments, although our own observations strongly support the 
lack of clinical efficacy. We undertook a long-term obser-
vational study of 136 sIBM patients of whom 71 patients 
(52 %) received immunosuppressive treatment [prednisone 
in 92 %, associated, in 65 %, with other immunomodula-
tory drugs (intravenous immunoglobulins, methotrexate 
or azathioprine)] for a median duration of 3.5 years [17]. 
At the last assessment, treated patients had not only not 
improved, but were more severely affected, based on dis-
ability scales (Walton p = 0.007, RMI p = 0.004) and on 
the sIBM weakness composite index (p = 0.04), than those 
who were not treated. The first stage of disease progression, 
towards handicap in walking, also occurred more rapidly 
among patients receiving immunosuppressive treatments 
(HR = 2.0, p = 0.002). We therefore concluded that immu-
nosuppressive treatments do not ameliorate, and may even 
aggravate, the natural course of sIBM [17]. We have to note 
that there are other presumed autoimmune conditions that 
show similar resistance to immunosuppressant therapy, 
notably multiple sclerosis (in its primary progressive form) 
and scleroderma. The immunosuppressant resistance may 
then not be a definite argument against the autoimmune 
nature of sIBM.
Arguments for inflammation as initial event/trigger
sIBM has been frequently described in association with 
other autoimmune disorders [15, 24, 53]. For instance, in 
a Dutch study of 52 sIBM patients, 17 patients (33 %) had 
associated autoimmune disorders including autoimmune 
thyroiditis (n = 6), rheumatoid arthritis (n = 4) and 
Sjögren syndrome (n = 4), with 3 patients with multiple 
autoimmune disorders [15]. The prevalence of autoantibod-
ies is also increased in sIBM [24, 80]. For instance, in an 
Australian study, 51 sIBM patients were compared to 198 
controls and the frequency of positive antinuclear autoanti-
bodies was higher in sIBM (29.4 vs. 8.6 %, p < 0.001), and 
among antibodies against extractable nuclear antigens (in 
order of their frequency), anti-SSA/Ro-52 or Ro-60, SSB/
La, RNP-A or C, and PM-Scl75 were statistically more fre-
quently observed in sIBM patients [80].
Recently, apparently sIBM-specific autoantibodies have 
been described. An antibody recognizing a 43 kD antigenic 
target was found in the serum of 13 out of 25 sIBM patients 
but not in 40 controls (healthy subjects or patients with 
other inflammatory myopathies) [86]. The antigenic target 
of this sIBM associated autoantibody has been identified by 
two independent teams as cytosolic 5′-nucleotidase 1A [56, 
76] an enzyme involved in nucleotide metabolism which 
is expressed at a relatively high level in skeletal muscle. 
Anti-NT5C1A autoantibodies were present in 33 % [76] 
and 34 % [56] of sIBM patients, as compared to ≤5 % in 
polymyositis and dermatomyositis [56, 76]. Nonetheless, 
the specificity of this new anti-NT5C1A autoantibody for 
the diagnosis of sIBM has not yet been fully evaluated and 
further studies are required, particularly in other groups 
of connective tissue diseases such as rheumatoid arthritis, 
lupus and systemic sclerosis. To date, our unpublished data 
suggests that this autoantibody can also be present in rheu-
matologic disorders such as lupus and Sjögren syndrome, 
so its specificity may not be as high as initial reports, in a 
more restricted group of patients, suggested.
Evidence for a sIBM-prone immunogenetic background 
comes from observations of a strong association with 
prominent alleles of HLA class I or II (such as alleles B8 
and notably DRbeta1*0301) [15, 53, 81], a situation not 
observed in hereditary inclusion body myopathies [53].
From a pathological point of view, Pruitt et al. [77] have 
shown that in muscle biopsies derived from 31 patients, 
the frequency of invaded fibres (mean 24.3/1,000) was sev-
eral fold higher than that of congo red positive fibres (mean 
3.1/1,000) or that of necrotic fibres (mean 3.1/1,000), and they 
concluded on the importance of an immune-mediated mecha-
nism in sIBM. Sarcolemmal HLA class I expression, which 
is absent in normal muscle [6], is upregulated in myositis in 
general [27] and in sIBM in particular [74]. The immunohis-
tological detection of HLA class I on the sarcolemma is thus 
considered to be a marker of myositis. In sIBM, the preva-
lence of HLA staining on muscle fibres is higher compared to 
dermatomyositis and polymyositis: expression of HLA class I 
was found in 67 % of muscle biopsies from patients with der-
matomyositis, in 61 % with polymyositis, and in 96 % with 
sIBM (on 208 analysed biopsies) [74].
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Finally, and in contrast to the observations noted above 
concerning the outcome of prospective, double-blind, stud-
ies of immunosuppressive therapies in sIBM, two clini-
cal trials, which included only a small number of patients, 
suggested that massive immunosuppression can lead to 
strength stabilization. The first compared six patients 
treated with anti-T lymphocyte globulin and methotrexate, 
with five patients treated with methotrexate only. The latter 
showed a significant loss of strength after 12 months but 
the anti-T lymphocyte globulin group remained stable [58]. 
In the second study, 13 patients were evaluated by quantita-
tive muscle strength testing to determine their natural his-
tory over 1 year. These patients were then treated by alem-
tuzumab (Campath™) and showed a transient stabilization 
of strength after 6 months [29]. Even if the results of the 
latter study have been debated [40], both studies suggest 
the possible involvement of adaptive immune responses in 
disease progression.
As indicated above, sIBM is accompanied by degenera-
tive protein accumulations, and deficient protein degrada-
tion pathways (both proteasomal and lysosomal) and one 
accumulated protein candidate might be HLA class I [36]. 
This situation exists in patients with a hereditary inclu-
sion body myopathy due to p97/VCP mutation, which is 
a complex responsible for the regulation of protein deg-
radation through these two pathways, but this hereditary 
inclusion body myopathy is not accompanied by signifi-
cant inflammation [49], neither the animal model [48]. 
In the same vein, the other classical hereditary inclusion 
body myopathy is caused by UDP-N-acetylglucosamine-
2-epimerase/N-acetylmannosamine kinase (GNE) gene 
mutation (leading to quadriceps-sparing myopathy). GNE 
encodes for a key enzyme in sialic acid biosynthesis and the 
myopathy is associated with the formation of autophagic 
vacuoles [61]. But this vacuolar myopathy is essentially 
not accompanied by muscle inflammation [25], except in 
three cases, from two families [5, 54]. Nevertheless and 
despite the general absence of inflammation, iNOS and 
αB-crystallin, two markers of cell stress, are present in nor-
mal appearing fibres of GNE patients and correlated with 
pro-inflammatory markers (such as IL-6), which remained 
expressed at levels comparable to control muscles [34]. 
Furthermore, mouse models of GNE do not show features 
of inflammation [105]. Experimentally, a transgenic mouse 
model of Finnish-type familial amyloidosis associated with 
gelsolin amyloidosis in skeletal muscle (with the gelsolin 
transgene under the control of a muscle specific promoter), 
is associated with amyloid deposits with foci of mono-
nuclear cell infiltration [71]. In a model with genetically 
augmented Aβ42 levels in skeletal muscle, there was no 
inflammation [50]. Hence, degenerative processes in mus-
cle induce cell stress but do not clearly and unequivocally 
elicit inflammation.
Influence of inflammation on amyloid deposits and/or 
muscle atrophy
In a sIBM transgenic mouse model, that is marked by 
enhanced levels of Aβ1-42 in skeletal muscle (of note, 
with no obvious muscle inflammatory infiltrates) [50], the 
long-term influence of inflammation, induced by chronic 
lipopolysaccharide injections, included increased Aβ gen-
eration and enhanced tau phosphorylation [51].
In muscle biopsies of sIBM patients, compared to other 
forms of myositis, Schmidt et al. [90] found that expres-
sion of the mRNA of β-amyloid precursor protein sig-
nificantly and consistently correlated with inflammation 
and enhanced mRNA levels of chemokines (CXCL-9, 
CCL-4 and CCL-3) and IFN-γ. To assess the influence of 
inflammation on β-amyloid accumulation, these authors 
performed in vitro experiments in human myotubes, and 
showed that exposure to IL-1β caused up-regulation of APP 
with subsequent intracellular aggregation of β-amyloid 
[90]. Furthermore, exposure to interleukin-1β, in com-
bination with interferon-γ induced intracellular produc-
tion of nitric oxide, was associated with necrotic cell 
death in muscle cells [91]. Hence, inflammation in muscle 
can elicit amyloid accumulation. On the other hand, by 
studying biopsies of sIBM patients before and after pred-
nisone ± polyvalent immunoglobulins, the same group 
[106] showed that these treatments decrease inflammation 
in muscle, but do not significantly suppress myotoxic and 
cell stress mediators such as nitric oxide.
As we have seen previously, various pro-inflammatory 
cytokines are secreted in the milieu of sIBM inflamma-
tory infiltrates, notably TWEAK [64]. TWEAK induces 
its effect through its receptor, the fibroblast growth factor-
inducible gene 14 receptor (Fn14), on neighbouring cells 
[104]. In sIBM muscle biopsies (but not in dermatomyosi-
tis nor in polymyositis) a dysregulation of the TWEAK-
Fn14 axis is observed, with an increase of its expression 
and secretion, which inhibited (in a reversible manner) the 
myogenic differentiation of mesoangioblasts [64]. TWEAK 
appeared then as a powerful muscle-wasting cytokine, 
inducing progressive muscle fibre atrophy, and simultane-
ously as a negative regulator of regenerative myogenesis 
[64].
Moreover, Rigyel et al. [85] have shown a correla-
tion between the number of invading CD3-positive cells 
(lymphocytes) or CD68-positive cells (macrophages) and 
COX-deficient muscle fibres (respectively, p = 0.007 and 
0.04). These correlations between the degree of inflam-
mation and signs of mitochondrial dysfunction strongly 
suggest a causative link between them. Furthermore, evi-
dence of mitochondrial dysfunction is also highly corre-
lated with fibre atrophy (p < 0.0001) [85]. The authors con-
cluded upon “a role for inflammatory cells in the initiation 
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of mitochondrial DNA damage, which when accumulated 
causes respiratory dysfunction, fibre atrophy and ultimately 
degeneration of muscle fibres” [85].
In conclusion: the chicken and the egg: which came 
first?
From the various arguments summarized above, a pos-
sible scenario for the pathogenesis of sIBM, and one that 
we favour, is that it may start with inflammation within 
muscle (of unknown aetiology but postulates include viral 
infections and muscle micro-trauma by eccentric exercise 
[99]) with the histological features long considered the hall-
mark of polymyositis (inflammatory cells, invasion of non-
necrotic muscle fibres, necrotic and regenerating muscle 
fibres, but without vacuoles or amyloid). Interestingly, pure 
polymyositis (i.e. without overlap clinical signs and/or with-
out myositis specific autoantibodies) appears, using current 
criteria, to be very rare [96], being described as an over-
diagnosed entity [63] and even as a mythological beast [3].
From a clinico-pathological standpoint, Chahin and 
Engel [24] showed that in 107 patients whose biopsies 
were initially read as polymyositis or sIBM, they were 
able to distinguish, by combining biopsy and clinical cri-
teria, a third group, which they called PM/IBM, with a 
biopsy diagnosis of polymyositis but with clinical features 
of sIBM. Arguably, this third group only exists because of 
adherence to earlier diagnostic criteria, and can be under-
stood better if it is accepted that patients with sIBM may 
not show the currently considered canonical pathological 
features at an early stage of the disorder. Most of the appar-
ently pure polymyositis cases might be, or become, sIBM, 
representing an intermediate phase falling into the PM/
IBM category [24]. In the same vein, Brady et al. [21] have 
shown in a series of 67 sIBM patients that the presence of 
rimmed vacuoles on muscle biopsy was more common in 
older patients (74 vs. 66 years; p = 0.04), suggesting that 
rimmed vacuoles may be a later feature of the disease. 
Moreover, no differences in disease characteristic or pro-
gression were observed between patients with or without 
vacuoles [21].
The rush of leukocytes, attracted by chemokines and 
cytokines, may induce fibre injury, mitochondrial dysfunc-
tion and HLA class I overexpression through, presumably, 
components of pro-inflammatory cell stress mechanisms 
Fig. 5  A possible scenario for the pathogenesis of sIBM is that it 
may start with inflammation within muscle (the different actors are 
represented in red). The rush of leukocytes attracted by chemokines 
and cytokines may induce fibre injury and HLA-I overexpression. If 
the protein degradation systems are overloaded (due to genetic pre-
disposition, particular HLA-I subtypes or ageing), amyloid and other 
protein deposits (represented in green) may appear within muscle 
fibres, reinforcing the myopathy in a vicious circle. The opposite 
scenario where amyloid deposits come first leading to a secondary 
inflammatory reaction is less probable since (apart some rare excep-
tions) neither hereditary inclusion body myopathy nor animal models 
of forced amyloid deposits (with proteasomal and/or autophagosomal 
pathway deficiencies) are accompanied by inflammation
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such as nitric oxide production [92]. If the protein deg-
radation systems are overloaded (perhaps failing to cope 
because of genetic predisposition, particular HLA class I 
subtypes or ageing), amyloid and other protein deposits 
may appear within muscle fibres, reinforcing the myo-
pathy in a vicious circle, which is clinically manifest as 
progressive muscle weakness. Figure 5 tries to summa-
rize these hypothetical physiological pathways starting 
from inflammation: the egg, if we accept that it came first! 
The opposite scenario, where amyloid deposits come first, 
leading to a secondary inflammatory reaction, is in our 
opinion, less probable since (apart some rare exceptions) 
neither hereditary inclusion body myopathy nor animal 
models of forced amyloid deposits (with proteasomal and/
or autophagosomal pathway deficiencies) are accompanied 
by inflammation.
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